{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T05:00:57Z","timestamp":1785042057594,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,25]]},"DOI":"10.7759\/cureus.113379","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:44:09Z","timestamp":1785041049000},"source":"Crossref","is-referenced-by-count":0,"title":["Sex-Specific Safety Signals of Finerenone Versus Spironolactone: Insights From the FDA Adverse Event Reporting System"],"prefix":"10.7759","author":[{"given":"Abhinandan","family":"Singla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurnoor","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivansh","family":"Luthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashaal S","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Kalsoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S","family":"Alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed S","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zulqarnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999, 341:709-17. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt B","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al.. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014, 370:1383-92. 10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad F","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364:11-21. 10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof P","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017, 234:T125-40. 10.1530\/JOE-16-0600","journal-title":"J Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2020.05.002","article-title":"Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration","volume":"6","author":"Wang Y","year":"2020","unstructured":"Wang Y, Lipner SR. Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration. Int J Womens Dermatol. 2020, 6:272-6. 10.1016\/j.ijwd.2020.05.002","journal-title":"Int J Womens Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.222","article-title":"Antithrombotic therapy in 2014: making headway in anticoagulant and antiplatelet therapy","volume":"12","author":"Fareed J","year":"2015","unstructured":"Fareed J. Antithrombotic therapy in 2014: making headway in anticoagulant and antiplatelet therapy. Nat Rev Cardiol. 2015, 12:70-1. 10.1038\/nrcardio.2014.222","journal-title":"Nat Rev Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker I","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020, 11:32. 10.1186\/s13293-020-00308-5","journal-title":"Biol Sex Differ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102060-00001","article-title":"Do women have more adverse drug reactions?","volume":"2","author":"Rademaker M","year":"2001","unstructured":"Rademaker M. Do women have more adverse drug reactions?. Am J Clin Dermatol. 2001, 2:349-51. 10.2165\/00128071-200102060-00001","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos G","year":"2021","unstructured":"Filippatos G, Anker SD, Agarwal R, et al.. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021, 143:540-52. 10.1161\/CIRCULATIONAHA.120.051898","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref12","article-title":"Finerenone: a new non-steroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes","volume":"56","author":"Yang P","year":"2022","unstructured":"Yang P, Cornelio RN, Reynoldson C. Finerenone: a new non-steroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Ann Pharmacother. 2022, 56:806-16.","journal-title":"Ann Pharmacother"},{"key":"ref13","unstructured":"US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. (2024). https.\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate A","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009, 18:427-36. 10.1002\/pds.1742","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda T","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013, 10:796-803. 10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek EP","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002, 11:3-10. 10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman KB","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014, 37:283-94. 10.1007\/s40264-014-0150-2","journal-title":"Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512881-sex-specific-safety-signals-of-finerenone-versus-spironolactone-insights-from-the-fda-adverse-event-reporting-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:44:22Z","timestamp":1785041062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512881-sex-specific-safety-signals-of-finerenone-versus-spironolactone-insights-from-the-fda-adverse-event-reporting-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.113379","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}